Xarelto（ACS/急性冠症候群）：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 17
3.1.1 Etiology 17
3.1.2 Pathophysiology 21
3.1.3 Prognosis 22
3.1.4 Quality of Life 23
3.2 Symptoms 23
4 Disease Management 25
4.1 Treatment Overview 25
5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 32
6 Unmet Need and Opportunity 37
6.1 Overview 37
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 38
6.2.1 Unmet Need 38
6.2.2 Gap Analysis 39
6.2.3 Opportunity 39
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 40
6.3.1 Unmet Need 40
6.3.2 Gap Analysis 41
6.3.3 Opportunity 41
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 42
6.4.1 Unmet Need 42
6.4.2 Gap Analysis 44
6.4.3 Opportunity 46
6.5 Antidotes for New Oral Anticoagulants (NOACs) 46
6.5.1 Unmet Need 46
6.5.2 Gap Analysis 47
6.5.3 Opportunity 47
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 48
6.6.1 Unmet Need 48
6.6.2 Gap Analysis 49
6.6.3 Opportunity 49
7 Pipeline Assessment 51
7.1 Overview 51
7.2 Clinical Trials by Phase and Trial Status 53
7.3 Promising Drugs in Clinical Development 55
8 Xarelto (rivaroxaban) 60
8.1 Overview 60
8.2 Efficacy 63
8.3 Safety 65
8.4 Dosing and Formulation 65
8.5 Potential Clinical Positioning 65
8.6 Potential Commercial Positioning 66
8.7 Pricing and Reimbursement 66
8.8 SWOT Analysis 67
8.9 Forecast 67
9 Appendix 70
9.1 Bibliography 70
9.2 Abbreviations 76
9.3 Methodology 80
9.4 Forecasting Methodology 80
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 80
9.4.2 Diagnosed Acute Coronary Syndrome Patients 81
9.4.3 Percent Drug-Treated Patients 82
9.4.4 General Pricing Assumptions 82
9.4.5 Generic Erosion 84
9.4.6 Pricing of Pipeline Agents 84
9.5 Physicians and Specialists Included in this Study 85
9.6 About the Authors 88
9.6.1 Author 88
9.6.2 Reviewer 88
9.6.3 Global Head of Healthcare 89
9.7 About GlobalData 90
9.8 Disclaimer 90